Mission Therapeutics Secures £32.18 Million in Funding Round to Advance DUB Therapeutics Pipeline

Mission Therapeutics, a pioneering private drug discovery and development company, has successfully raised an impressive £32.18 million ($40 million) in its latest funding round. This financial boost will be instrumental in advancing the company’s innovative platform, which specializes in selectively targeting deubiquitylating enzymes (DUBs). Known for their potential to revolutionize treatment for diseases with high unmet medical needs, DUBs represent an emerging drug class that is rapidly gaining attention within the pharmaceutical industry—often referred to as the ‘Next Kinase Area’. With this new funding, Mission Therapeutics aims to further develop its rich pipeline of first-in-class small-molecule drugs, advancing them through early clinical trials with a strategic focus on patient selection to enhance the likelihood of demonstrating initial efficacy. The company, which is headquartered at the Babraham Research Campus near Cambridge, is supported by a formidable leadership team with extensive expertise in commercial and scientific realms, and it has established robust partnerships with leading academic institutions, including Cancer Research UK Laboratories and the Jackson Laboratories at the University of Cambridge’s Gurdon Institute. This latest round of funding underscores the confidence investors have in Mission's vision and capacity to deliver groundbreaking therapies. Since its inception, Mission Therapeutics has raised a total of £87 million in venture capital and has actively sought collaborations that align with its mission of transforming patient outcomes in previously intractable diseases.